Since then, several trials have been designed to combine chemotherapy with ICIs, including anti-CTLA4, anti-PD-1 or anti-PD-L1, as a first line therapy for ED-SCLC [13,14,15,16,17,18]. Here, CTLA4 is linked to small cell lung carcinoma.